Renal Biomarkers for Treatment Effect of Ranibizumab for Diabetic Macular Edema

Table 1

Demographic data, visual acuity, optical coherence tomography characteristics, and injection number in four different proteinuria groups at baseline.

	A: normal to mildly increased proteinuria ()	B: moderately increased proteinuria ()	C: severely increased proteinuria ()	D: dialysis ()	value
					A vs. B	A vs. C	A vs. D
Age (year)					0.41	0.74	0.13
Sex (female)	44%	69%	63%	18%	0.29	0.24	0.23
Hypertension	56%	56%	88%	73%	1	0.011	0.44
HbA1c (%)					0.50	0.45	0.027
DR staging					0.13	0.23	0.75
Mild NPDR	6%	0%	0%	9%
Moderate NPDR	25%	6%	14%	9%
Severe NPDR	31%	19%	30%	27%
Treatment-naive PDR	19%	19%	16%	18%
PDR with PRP	19%	56%	40%	36%
LogMAR of BCVA					0.84	0.56	0.26
CFT (μm)					0.025	0.49	0.19
Intraretinal cysts	75%	100%	93%	100%	0.10	0.078	0.12
Subretinal fluid	19%	25%	21%	9%	1	1	0.63
Injection number					0.008	0.015	0.41

CFT: central foveal thickness; DR: diabetic retinopathy; eGFR: estimated glomerular filtration rate; LogMAR of BCVA: logarithm of the minimum angle of resolution of best-corrected visual acuity; NPDR: nonproliferative diabetic retinopathy; PDR: proliferative diabetic retinopathy; PRP: panretinal photocoagulation.